President Donald Trump signed a new executive order aimed at lowering drug prices in the United States by linking them to those of other nations and expanding the scope of a July 2020 action.
U.S. President Donald Trump signed four executive orders aiming at lowering prices that Americans pay for prescription drugs as he faces an uphill re-election battle and criticism over his handling of the coronavirus pandemic.
Roche struck a $1.7 billion cancer drug pact with Blueprint Medicines, as advances in genetic testing for rare mutations drive lucrative deals for expensive treatments.
Twenty-six drug manufacturers were sued by the attorneys general of most U.S. states and several territories, which accused them of conspiring to reduce competition and drive up generic drug prices.
Even as lawmakers debate and malign proposed plans to lower the costs of prescription drugs in the United States, since the start of 2020, prices increased on more than 600 prescription drugs by an average of 5.2 percent.
Chants of “H.R. 3” broke out in the House of Representatives chamber during the 2020 State of the Union Address as Democratic lawmakers urged action on the bill passed late last year that could impact the price of prescription medications paid for by government-funded health programs.
Roche company Genentech announced positive top-line results from the pivotal Part 2 of the FIREFISH study looking at risdiplam in infants aged 1-7 months with Type 1 spinal muscular atrophy (SMA).
In August 1963, the Rev. Martin Luther King delivered his famous “I Have a Dream” speech that called for equality among all people, regardless of their ethnicity, as well as a vision for a better America for all. While the noble dreams that King outlined on that hot day in Washington, D.C. so many years ago have unfortunately not yet been fully realized, there are other kinds of dreams that may be closer to being achieved, particularly in the area of new medications for serious diseases.
As the J.P. Morgan Healthcare Conference entered the final day for 2020, a few topics rose to the top as trending, including the relative lack of big deals.
With the 2020 elections looming though, and lawmakers across the country drafting legislation aimed at curbing price increases, some companies are carefully examining the landscape as they approach pricing.